The United
Kingdom Breast Cancer Therapeutics Market is poised for significant growth in
the projected period of 2028. Breast cancer continues to be a major public
health concern in the United Kingdom, posing challenges for individuals,
medical professionals, and researchers alike. However, advancements in breast
cancer therapies have led to more effective treatment options and improved
quality of life for patients. The United Kingdom boasts a robust healthcare
system, particularly one that prioritizes breast cancer care.
Breast
cancer is characterized by the uncontrolled proliferation of cells in the
breast. There are various forms of breast cancer, with the type determined by
the specific cells involved. Different regions of the breast can be affected by
breast cancer, which consists of connective tissue, ducts, and lobules. Lobules
are responsible for milk production, while milk is transported through ducts to
the nipple. Connective tissue provides support and envelops the structures of
the breast. Most breast cancers originate in the ducts or lobules.
The United
Kingdom's breast cancer therapeutics market is projected to experience
substantial growth in the coming years. Factors such as increasing disease
prevalence, growing awareness, and advancements in treatment options are
driving market expansion. Moreover, collaborations between academic
institutions, research organizations, and pharmaceutical companies are
fostering innovation and accelerating the development of novel therapies. The
field of breast cancer research is continuously evolving, with several
promising therapies currently in development. These include antibody-drug
conjugates, PARP inhibitors, and PI3K inhibitors, among others. These
innovative therapies specifically target vulnerabilities in breast cancer cells
and hold potential for further enhancing patient outcomes, particularly in
cases that are resistant or advanced, thus contributing to the growth of the
United Kingdom Breast Cancer Therapeutics Market.
Another
significant advancement in breast cancer therapeutics is the emergence of
immunotherapy. Immune checkpoint inhibitors, such as pembrolizumab, have shown
promising results in patients with advanced triple-negative breast cancer, a
subtype that has traditionally been challenging to treat. Immunotherapies
harness the body's immune system to recognize and eliminate cancer cells,
offering new hope to patients who previously had limited treatment options.
This is expected to drive the growth of the United Kingdom Breast Cancer
Therapeutics Market.
Rising Prevalence of Breast Cancer Will Spur the Demand for Breast
Cancer Therapeutics
The United Kingdom is faced with a significant burden of
breast cancer, a devastating disease that claims numerous lives annually. Among
women in the United Kingdom, breast cancer is the most prevalent form of
cancer, with its incidence steadily increasing. This rise in breast cancer
cases has driven the growth of the United Kingdom Breast Cancer Therapeutics
Market, as healthcare providers and pharmaceutical companies strive to develop
innovative treatments and improve patient outcomes. Several factors, including
an aging population, changing lifestyle patterns, and improved screening and
diagnostic methods, have contributed to better detection and reporting of
breast cancer cases. According to the International Agency for Research on
Cancer, there were 53,889 new cases of breast cancer reported in the United
Kingdom in 2020, accounting for 11.8% of all new cancer cases, totaling
457,960. While multiple factors contribute to the development of breast cancer,
an unhealthy lifestyle remains a significant driver. Exposure to the drug
diethylstilbestrol (DES) remains the primary cause of breast cancer, and the
high rates of obesity in the United Kingdom further exacerbate the problem, as
excess body weight is associated with an elevated risk of breast cancer. The
link between diet, obesity, and breast cancer underscores the need for
therapeutics to manage and treat the disease. According to NHS Digital, 25.9%
of adults in England are obese, and an additional 37.9% are overweight but not
obese, with obesity defined as having a body mass index (BMI) of 30 or above.
While lifestyle choices play a significant role in the development of breast
cancer, environmental factors should not be overlooked. Women who experience
menstruation before the age of 12 and menopause after the age of 55 are exposed
to hormones for a longer period, increasing their risk of developing breast
cancer and contributing to the expansion of the United Kingdom Breast Cancer
Therapeutics Market. Moreover, awareness campaigns and initiatives by organizations
and healthcare providers have played a crucial role in promoting early
detection of breast cancer in the United Kingdom. Public awareness programs,
including breast self-examination campaigns and routine mammography screenings,
have contributed to the identification of breast cancer at earlier stages,
allowing for more effective treatment interventions and increasing the chances
of successful outcomes. According to the Office for National Statistics, the
estimated healthcare cost in the UK was USD 350.83 billion in 2022,
representing a nominal increase of 0.7% compared to 2021.
Expanding Revolutionary New Technology Drives the United Kingdom Breast
Cancer Therapeutics Market
In the United Kingdom,
significant progress has been made in the battle against breast cancer,
particularly with the emergence of advanced radiation techniques. The
development of targeted therapies, specifically immune checkpoint inhibitors
and antibody-drug conjugates, has garnered tremendous attention in fighting
breast cancer, revolutionizing its treatment. These cutting-edge treatments
offer new hope to patients, propelling the growth of the United Kingdom Breast
Cancer Therapeutics Market.
Immune checkpoint inhibitors, a class of drugs that assist the body's
immune system in recognizing and attacking cancer cells, play a crucial role in
this fight. By blocking the proteins that hinder immune cells from identifying
and eliminating cancer cells, these drugs demonstrate their efficacy in
treating breast cancer. Multiple clinical trials are currently ongoing in the
United Kingdom to assess the safety, effectiveness, and potential of immune
checkpoint inhibitors in breast cancer treatment. The outcomes of these trials
are expected to enhance patient outcomes and contribute to the growth of the
United Kingdom Breast Cancer Therapeutics Market.
The introduction of these novel technologies has significantly impacted
the United Kingdom Breast Cancer Therapeutics Market. The availability of
targeted therapies has opened up new avenues for personalized and precision
medicine, providing patients with tailored treatment options based on their
tumor characteristics. Furthermore, these advancements have the potential to
improve patient outcomes by increasing response rates and extending survival.
In response to this progress, the United Kingdom has witnessed a surge
in investments and research collaborations focused on developing and
commercializing these innovative treatments. Pharmaceutical companies,
biotechnology firms, and research institutions are actively engaged in clinical
trials and the development of new drug candidates, aiming to bring these
therapies to market. This increased research and development activity has
fostered competition among market players, driving innovation and fueling the
growth of the breast cancer therapeutics market in the United Kingdom.
Moreover, the introduction of novel technologies has spurred
advancements in diagnostic techniques, enabling early detection and better
patient stratification. The integration of biomarkers and genetic testing has
facilitated the identification of patients who are most likely to benefit from
these targeted therapies. This approach not only optimizes treatment outcomes
but also helps reduce healthcare costs by avoiding ineffective treatments.
Recent Developments
- In March 2023, Novartis AG NVS released positive
top-line results from an interim analysis of the late-stage NATALEE study
on the breast cancer medication Kisqali.
- In May 2023, Dr Anita Grigoriadis, from
King’s College London, created a system to estimate the risk of cancer
spreading by keeping an eye out for early changes in the lymph nodes under
the armpit. For women with triple-negative breast cancer, of which there
are about 8,000 per year, it can be used in the very early stages of the
disease. AI can predict what a cancer will most likely do next by
comparing a woman's lymph nodes to those of previous patients.
Market Segmentation
The United Kingdom
Breast Cancer Therapeutics Market is classified into Therapy, End User, and
company. In terms of Therapy, the market is segmented into Chemotherapy,
Hormone Therapy, Immunotherapy, Targeted Therapy, and Others. The End User
segment includes Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and
Others. Geographically, the market is divided into Scotland, South-East,
London, South-West, East-Anglia, Yorkshire & Humberside, and East Midlands.
Company Profiles
Novartis AG, Pfizer Inc,
Eli Lilly & Company, Merck Co. & Inc., GlaxoSmithKline, Plc., AstraZeneca
Plc, Bristol-Myers Squibb Company, Eisai Co., Ltd., Sanofi S.A., Mylan NV are some
of the key players of United Kingdom Breast Cancer Therapeutics market.
Download Free Sample Report
Attribute | Details |
Base
Year | 2022 |
Historic Data | 2018 – 2021 |
Estimated
Year | 2023 |
Forecast Period | 2024 – 2028 |
Quantitative
Units | Revenue in USD Million and CAGR for 2018-2022 and 2023-2028 |
Report coverage | Revenue forecast, company
shares, competitive landscape, growth factors, and trends |
Segments
covered | Therapy
End
User Region
|
Country scope | Scotland, South-East,
London, South-West, East-Anglia, Yorkshire & Humberside, and East
Midlands |
Key companies profiled | Novartis
AG, Pfizer Inc, Eli Lilly & Company, Merck Co. & Inc.,
GlaxoSmithKline, Plc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eisai
Co., Ltd., Sanofi S.A., Mylan NV |
Customization
scope | 10% free report customization with purchase. Addition or alteration
to country, regional & segment scope. |
Pricing and purchase options | Avail customized purchase
options to meet your exact research needs. |
Delivery
Format | PDF and Excel through Email (We can
also provide the editable version of the report in PPT/Word format on special
request) |
Report Scope:
In this report, United Kingdom Breast Cancer Therapeutics Market
has been segmented into the following categories, in addition to the industry trends,
which have also been detailed below:
- United Kingdom Breast Cancer Therapeutics
Market, By Therapy:
- Chemotherapy
- Hormone Therapy
- Immunotherapy
- Targeted Therapy
- Others
- United Kingdom Breast Cancer
Therapeutics Market, By End User:
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Others
- United Kingdom Breast Cancer
Therapeutics Market, By Region:
- Scotland
- South-East
- London
- South-West
- East-Anglia
- Yorkshire & Humberside
- East Midlands
Competitive landscape
Company Profiles: Detailed analysis of the major companies in United
Kingdom Breast Cancer Therapeutics market.
Available Customizations:
With the
given market data, TechSci Research offers customizations according to a company’s
specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of
additional market players (up to five).
United Kingdom Breast
Cancer Therapeutics Market is an upcoming report to be released soon. If you wish
an early delivery of this report or want to confirm the date of release, please
contact us at [email protected]